Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.54 |
| ▸ | WNT3A | P56704 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889161 | 0.97 | CES2 (0.56) | CES2CES1CTNNB1WNT3ANPC1 | |
| SCHEMBL30416977 | 0.91 | CTNNB1 (0.60) | CES2CES1CTNNB1WNT3ANPC1 | |
| SCHEMBL3588375 | 0.91 | CTNNB1 (0.60) | CES2CES1CTNNB1WNT3ANPC1 | |
| SCHEMBL28188567 | 0.86 | PDE4B (0.67) | CES2CES1CTNNB1WNT3ANPC1 | |
| SCHEMBL7389569 | 0.85 | CES2 (0.56) | CES2CES1CTNNB1WNT3ANPC1 | |
| SCHEMBL4638591 | 0.84 | CES2 (0.59) | CES2CES1CTNNB1WNT3ANPC1 | |
| SCHEMBL28133957 | 0.84 | PARP1 (0.53) | CES2CES1CTNNB1WNT3ANPC1 | |
| SCHEMBL2130116 | 0.84 | CES2 (0.62) | CES2CES1CTNNB1WNT3ANPC1 | |
| SCHEMBL30626936 | 0.84 | CES2 (0.62) | CES2CES1CTNNB1WNT3ANPC1 | |
| SCHEMBL4884872 | 0.83 | PDE4B (0.62) | CES2CES1CTNNB1WNT3ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104250236-B | γ hydrocarbon oxygen sulfonylmethyl gamma butyrolactone, the synthetic method of δ hydrocarbon oxygen sulfonylmethyl δ valerolactone | 大连大学 | 2017-03-01 | — | — | CN | disclosed |
| US-8236818-B2 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2144907-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008116665-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| EP-1974729-A1 | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | MC4R, MC3R, MC5R | CES2 4645/4885CES1 4666/4885CTNNB1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.